Drug intelligence / Profile preview

salmeterol + fluticasone (GSK)

Development stage
Approved
Lead developer
GSK
Modality
Small Molecules
Administration
Inhalation
01

Overview

Salmeterol + fluticasone is a combination medication used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for the relief of acute symptoms or attacks. The combination contains two active ingredients: fluticasone propionate (an inhaled corticosteroid) and salmeterol xinafoate (a long-acting beta-agonist). Fluticasone reduces inflammation in the airways by inhibiting inflammatory mediators, while salmeterol relaxes bronchial smooth muscle by stimulating beta-2 adrenergic receptors, leading to bronchodilation. This dual mechanism helps prevent asthma attacks and COPD exacerbations when used regularly as prescribed[1][2][7].

Brand names
Advair DiskusAdvair HFAAirDuo RespiclickAirDuo DigihalerWixela Inhub
Other names
fluticasone and salmeterol inhalation
02

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on salmeterol + fluticasone (GSK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on salmeterol + fluticasone (GSK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call